Differentiated mu-opioid receptor pre-development candidates for the treatment of pain, plus backup molecules.
Based on in vitro and in vivo profiles, our assets are expected to be differentiated therapeutics for the treatment of pain with diminished on-target adverse effects.
In progress and under consideration are GPCR targets involved in neurodegenerative disorders, mood disorders, pain (non-opioid), cardiovascular, and immuno-onocology.
Superior to Standard of Care
Clear bias SAR established with strong G-protein agonism
in vivo data show greater therapeutic index due to diminished adverse effects resulting from bias agonism
Provisional patent filed September 1, 2016 Application No. 62/382,530 on Chemotype A: The MEB-9961 series
Provisional patent filed January 17, 2017 Application No. 62/447,197 on Chemotype B: The MEB-1097 series